Alexion Pharma International Operations Unlimited Company, commonly referred to as Alexion Pharmaceuticals, is a leading biopharmaceutical firm headquartered in Ireland (IE). Founded in 1992, the company has established a strong presence in the global pharmaceutical industry, focusing on the development of innovative therapies for rare and complex diseases. With major operational regions across North America, Europe, and Asia, Alexion is renowned for its pioneering work in complement inhibition, particularly through its flagship products like Soliris and Ultomiris. These therapies are unique for their ability to address life-threatening conditions such as paroxysmal nocturnal haemoglobinuria and atypical haemolytic uraemic syndrome. Alexion's commitment to advancing patient care has positioned it as a market leader, achieving significant milestones in research and development, and earning recognition for its contributions to the field of rare disease treatment.
We don't have data for Alexion Pharma International Operations Unlimited Company, but we can show you information about their parent organization instead.
View parent company